
Sirius Therapeutics Reports Promising Phase I Data for Next-Gen Anticoagulant
Sirius Therapeutics has announced promising preliminary results from its Phase 1 first-in-human clinical trial of SRSD107, a next-generation siRNA therapeutic under development for the prevention and treatment of thromboembolic disorders. These include conditions such as myocardial infarction, ischemic stroke, and…